T淋巴细胞如何被激活?
细胞治疗领域中T细胞的激活
为支持细胞治疗药物的开发，ACROBiosystems 自主开发了高质量的CD3/CD28抗体偶联磁珠产品（货号：MBS-C001），经细胞水平验证，可高效刺激扩增T细胞，更好的助力细胞治疗药物的开发进程。
★ 5.5 μm大小，可更好的模拟APC，刺激T细胞
★ 磁性强，轻松分离，磁珠不易残留
★ 超低内毒素（< 2EU/mg），对T细胞无伤害
★ 经细胞水平验证，可高效激活扩增T细胞
☛ Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No. MBS-C001) 可高效激活T细胞
☛ 经Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No. MBS-C001) 刺激后，可对T细胞进行有效扩增
竞品对比数据
The purified human T cells were activated using ACRO Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No. MBS-C001) and competitor’s beads respectively at a ratio of 1:1 beads-to-cells for 24 hours with RPMI1640 supplemented with 10% of FBS. Cells were fluorescently stained using PE labeled anti-human CD25 antibody and labeled FITC anti-human CD69 antibody and analyzed by flow cytometry.
与竞品相比，ACRO Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No. MBS-C001)，可对T细胞进行有效扩增，且有较高水平的扩增能力
The purified human T cells were stimulated using Anti-CD3/CD28 Antibody-coupled Magnetic Beads (Cat. No. MBS-C001) and competitor’s beads respectively. Cells were expanded in T cell culture medium supplemented with 4ng/mL of rhIL-2 Protein (Acrobiosystems, Cat. No. IL2-H4113). Activated Cells were expanded for up to 13 days (A) with high cell viability (B).
★更多T细胞激活试剂Anti-CD3 antibody（clone: OKT3Anti-CD28 antibod
GMP级别细胞因子
ACROBiosystems
inquiry@acrobiosystems.com
15117918562
（备注：姓名+公司）
参考文献
[1] Kay, J.E., 1991. Mechanisms of T lymphocyteactivation. Immunology Letters 29, 51 – 54
[2] 医学免疫学-第7版
[3] Trickett A, Kwan YL. T cellstimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods. 2003Apr 1;275(1-2):251-5.
[4] Kalos M, Levine BL, Porter DL, KatzS, Grupp SA, Bagg A, June CH: T cells with chimeric antigen receptors havepotent antitumor effects and can establish memory in patients with advancedleukemia. Sci Transl Med 2011, 3:95ra73.
[5] Hollyman D, Stefanski J, PrzybylowskiM, Bartido S, Borquez- Ojeada O, Taylor C, Yeh R, Capacio V, Olszewska M, HoseyJ et al.: Manufacturing validation of biologically functional T cells targetedto CD19 antigen for autologous adoptive cell therapy. J Immunother 2009, 32:169-180.
[6]Casati A, Varghaei-Nahvi A, FeldmanSA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A: Clinical-scaleselection and viral transduction of human naı¨ve and central memory CD8+ T cells for adoptive cell therapy ofcancer patients. Cancer Immunol Immunother 2013, 62:1563-1573.
[7] Barrett DM, Singh N, Liu X, JiangS, June CH, Grupp SA, Zhao Y: Relation of clinical culture method to T-cellmemory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy2014, 16:619-630.